Puretech Health Share Discussion Threads

[rambutan2] 22/1/2020 01:31

Yes, was also unclear re raise. But had a look and as far as I can see it closed not long after. However, I'm not up to speed on the US disclosure system, which I find unclear.

[edwardt] 21/1/2020 20:02

Karuna starting to motor again...

[edwardt] 20/1/2020 11:51

when does that raise close? also is it not set at below the current share price now? sorry for being lazy!

[rambutan2] 19/1/2020 20:10

Listened to the Karuna presentation. Rather compelling. I assume reason for KRTX jumping back over $100 by fri close.

[edwardt] 16/1/2020 18:33

What happened to the idea of dual listing?

[rambutan2] 15/1/2020 20:34

Re KRTX, we hold 7,395,397 ords, which constitutes a 28.4% stake post recent raising. And at current $84 adds up to $621m/£477m.


Major shareholders are on pg168 below:

[rambutan2] 15/1/2020 20:12

And Akili not disappointing - but still awaiting FDA nod:

PureTech Affiliate Akili Announces New AKL-T01 Study Achieved Primary Endpoint in Children with ADHD

AKL-T01 showed statistically significant improvement in ADHD Impairment Rating Scale (IRS), when used alone and as adjunct to stimulants

Akili continues to pursue FDA clearance for AKL-T01 as a potential treatment of inattention in paediatric ADHD

PureTech Health plc (LSE: PRTC) ("PureTech") is pleased to note that its affiliate, Akili, today announced top-line results of its multi-site open-label study (STARS-ADHD Adjunctive) to evaluate the effects of AKL-T01 in children with Attention Deficit Hyperactivity Disorder (ADHD) when used with and without stimulant medication. The effects of increasing the duration of treatment were also studied. The study achieved its predefined primary efficacy outcome, demonstrating a statistically significant improvement in the ADHD Impairment Rating Scale (IRS) from baseline after one month of treatment (p<0.001) in both children taking stimulant medications and in those not taking stimulants.

Eric Elenko, PhD, chief innovation officer at PureTech, said: "We are pleased with these new results as they provide additional support for AKL-T01 in paediatric ADHD - both as a monotherapy and in combination with stimulant medications. This study also builds on the previously reported cognition findings by demonstrating efficacy on the IRS, which is a scale of ADHD-specific symptoms that provides measures of the real-world consequences of ADHD symptoms."

[rambutan2] 15/1/2020 20:10

Will be worth a listen:

Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Steve Paul, M.D., chief executive officer, president and chairman of Karuna Therapeutics, will present at the 38th Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, CA. The Company is scheduled to present on Thursday, January 16, 2020, at 11:00 a.m. PT.

Karuna recently announced that KarXT met its primary endpoint in the Phase 2 clinical trial studying KarXT in acute psychosis in patients with schizophrenia. The company will discuss these results and other business updates during its presentation.

A live webcast will be available (here - ). After the live webcast of the presentation, the event will remain archived for 30 days.

[edwardt] 02/1/2020 09:13

Nice article in lex on akili

[wantage] 30/12/2019 11:44

Has it been tipped?

[rambutan2] 24/12/2019 01:57

Has Karuna read through:

[lendmeafiver] 23/12/2019 13:53

Looking encouraging to finally break £3, the follica medical device must be worth something reasonable with those results surely.

[bahiflyer] 19/12/2019 19:52

Positive update from Follica today and Karuna share price picking up after the consolidation around $60. Breakthrough of £3 again soon and reasonably expect an uptrend towards £4.

[lendmeafiver] 12/12/2019 14:19

Further good newsflow, get us on the Nasdaq please.

[rambutan2] 10/12/2019 21:00

Yes, it's going for a world record in Price Monitoring Extensions!

[lendmeafiver] 10/12/2019 19:19

Further good news flow here today and KRTX looking solid, whilst the PRTC share price seems to be all over the place on minimal volume.

[rambutan2] 09/12/2019 19:59

I note that post raise, PRTC's stake has risen slightly, from 19.5% to 22.3%. Which seems slightly odd, but nothing to ponder on for too long.

PureTech's percentage ownership of Gelesis following the financing is approximately 22.3% on a diluted basis. This calculation of PureTech's holding includes issued and outstanding shares as well as options and warrants to purchase shares, but excludes unallocated shares authorised to be issued pursuant to equity incentive plans. PureTech Health also has a right to low single-digit royalty payments as a percentage of net sales of certain Gelesis products. Of the $63.4 million equity raised in this financing by Gelesis, Invesco Asset Management subscribed for 949,623 preferred shares for an aggregate purchase price of $16.4 million. Invesco is a substantial shareholder of PureTech pursuant to the Listing Rules, and thus this transaction is a smaller related party transaction falling within the scope of Listing Rule 11.1.10R. Invesco was a shareholder of Gelesis prior to this financing and its percentage ownership is substantially the same before and after the financing.

[rambutan2] 09/12/2019 19:52

Gelesis Secures Over $84 Million in New Capital to Support Commercialisation of PLENITY(TM)

Vitruvian Partners leads a $63.4 million equity round, complemented by $21.2 million in new, non-dilutive grant funding and loans to further support commercialisation efforts...

[rambutan2] 03/12/2019 18:53

Plenty of news t/c over the next 12mths...

[lendmeafiver] 25/11/2019 09:56

Peel Hunt have raised the target price to 460p I believe.

[lendmeafiver] 22/11/2019 23:24

The £210m must be broadly covered by cash alone, ridiculous.

[lendmeafiver] 22/11/2019 23:05

Everything else valued at £210m, ridiculous

[rambutan2] 22/11/2019 22:12

Yes, KRTX closed the week at $85, so that covers £490m of our mkt cap, which was £800m at lights out.

[lendmeafiver] 22/11/2019 16:16

It is very surprising just how little the transformation in KRTX has been reflected here, to date anyway.

[wantage] 22/11/2019 16:04

Interesting to see comparison between share prices of Krtx and pure tech. Just bought 175 shares in krtx and bought some pure tech a couple of days ago.